271247-49-5

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 271247-48-4 3-(2-methylsulfonylpyrimidin-4-yl)-4-(3-trifluoromethylphenyl)-6-(N-carbobenzoxypiperidin-4-yl)pyridazine 
• 271247-47-3 3-(2-methylthiopyrimidin-4-yl)-4-(3-trifluoromethylphenyl)-6-(N-carbobenzoxypiperidin-4-yl)peridazine 
• 443958-81-4 1-(2-methylthiopyrimidin-4-yl)-1-oxo-2-(3-trifluoromethylphenyl)-4-oxo-4-(N-carbobenzoxypiperidin-4-yl)butane 
• 271247-45-1 1-(2-methylthiopyrimidin-4-yl)-1-oxo-2-(3-trifluoromethylphenyl)ethane 
• 271247-59-7 2-methylsulfanyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide 
• 705-29-3 3-Trifluoromethylbenzyl chloride 

Relevant academic research and scientific papers

Pyridazine based inhibitors of p38 MAPK

Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group α and a heteroaryl group β relative to the nitrogen atom in the 2-position of the central pyridazine.

Compounds having cytokine inhibitory activity

There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.